AML
Showing 1 - 25 of 2,908
AML, Adult, Minimal Residual Disease Trial in Guangzhou (chidamide and azacitidine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- chidamide and azacitidine
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Sep 27, 2023
AML, Adult Trial (Biological characterization of AML with MECOM or atypical 3q26 rearrangements)
Not yet recruiting
- AML, Adult
- Biological characterization of AML with MECOM or atypical 3q26 rearrangements
- (no location specified)
Apr 21, 2023
Assessment of Geriatric Evaluations Impact on New AML Guidance
Not yet recruiting
- AML, Adult
-
Philadelphia, PennsylvaniaAbramson Cancer Center at University of Pennsylvania
Jun 12, 2023
AML Trial in Berne (Image-based ex-vivo drug screening platform (pharmacoscopy))
Recruiting
- AML
- Image-based ex-vivo drug screening platform (pharmacoscopy)
-
Berne, SwitzerlandDepartement of Medical Oncology, University Hospital Berne
Feb 8, 2023
Acute Myeloid Leukemia in Children Trial (Standard Intervention, Investigational Intervention)
Not yet recruiting
- Acute Myeloid Leukemia in Children
- Standard Intervention
- Investigational Intervention
- (no location specified)
Aug 8, 2023
AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)
Not yet recruiting
- AML/MDS
- +2 more
- Danvatirsen
- Danvatirsen + Venetoclax
- (no location specified)
Aug 14, 2023
Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors Trial in Suzhou (Avapritinib)
Recruiting
- Core Binding Factor Acute Myeloid Leukemia
- KIT Mutation-Related Tumors
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital of Soochow University
Apr 7, 2023
AML, Adult Trial (Pharmacoscopy, Clinical standard-of-care (physician's choice))
Not yet recruiting
- AML, Adult
- Pharmacoscopy
- Clinical standard-of-care (physician's choice)
- (no location specified)
Nov 20, 2023
Essential Hypertension Trial (AZM X mg + AML Y mg, AZM X mg + AML Y' mg, AZM X' mg + AML Y mg)
Not yet recruiting
- Essential Hypertension
- AZM X mg + AML Y mg
- +7 more
- (no location specified)
May 25, 2022
Relapsed/Refractory AML Trial in Suzhou (Selinexor, Homoharringtonine, Cytarabine)
Not yet recruiting
- Relapsed/Refractory AML
- Selinexor
- +6 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Mar 28, 2023
Acute Myeloid Leukemia Trial (MCBC regimen, Bu/Cy regimen)
Not yet recruiting
- Acute Myeloid Leukemia
- MCBC regimen
- Bu/Cy regimen
- (no location specified)
Nov 13, 2023
Acute Myeloid Leukemia (AML) Trial in Nantes (Siltuximab)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
-
Nantes, FranceCHU de Nantes
Jan 24, 2023
Immunophenotyping of Blast Cells and Immune Effector Cells in
Completed
- Leukemia
- Blood and Marrow sample
-
Marseille, FranceAssistance Publique - Hopitaux de Marseille
Jan 23, 2023
Acute Myeloid Leukemia (AML) Trial in Nantes (Tocilizumab)
Active, not recruiting
- Acute Myeloid Leukemia (AML)
-
Nantes, FranceCHU of Nantes
Dec 16, 2022
AML Including AML de Novo and AML Secondary to MDS, DLBCL Trial (Birabresib Dose 20 mg)
Terminated
- AML Including AML de Novo and AML Secondary to MDS
- DLBCL
- Birabresib Dose 20 mg
- (no location specified)
Aug 23, 2022
AML, Adult Trial in Berne (HDM201, Midostaurin)
Terminated
- AML, Adult
-
Berne, SwitzerlandDepartement of Medical Oncology, University Hospital Berne
Oct 3, 2022
CBFA2T3-GLIS2-positive Acute Myeloid Leukemia, AML, Childhood, Relapsed Pediatric AML Trial (ELU001)
Not yet recruiting
- CBFA2T3-GLIS2-positive Acute Myeloid Leukemia
- +3 more
- (no location specified)
Nov 14, 2022
AML, Acute Myeloid Leukemia Trial in Boston (DREAMLAND, CERENA)
Not yet recruiting
- AML
- Acute Myeloid Leukemia
- DREAMLAND
- CERENA
-
Boston, MassachusettsMassachusetts General Hospital
Aug 12, 2022
AML Trial in Wuhan (CAR--?dT cells)
Recruiting
- AML
- CAR--γδT cells
-
Wuhan, Hubei, ChinaTongji Hospital
May 24, 2022
Acute Myeloid Leukemia Trial in Baltimore (Decitabine, talazoparib)
Active, not recruiting
- Acute Myeloid Leukemia
-
Baltimore, MarylandUniversity of Maryland Greenebaum Comprehensive Cancer Center
May 31, 2022